How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

It's an upgrade worth making, but it comes down to your privacy concerns.

Buffer overflow vulnerabilities have driven remote code execution for decades and keep appearing in critical network ...

On Wednesday, OpenAI took its biggest step yet towards full technological independence with the unveiling of a new AI chip, dubbed Jalapeño, that it developed in collaboration with U.S. chipmaker ...

Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...

AI isn't failing because models are bad; it's struggling because most industries lack the structured workflows needed to ...

Covering more ground faster creates better outcomes only if you know which direction to run. Over the course of my career, ...

Vitalik Buterin outlined the updated Lean Ethereum roadmap, a 3-to-4-year plan covering quantum resistance, 10,000 TPS ...

As organizations race to adopt artificial intelligence, the conversation has increasingly shifted from raw model performance ...

What happened Security researchers disclosed multiple vulnerabilities affecting Apple AirDrop and Google and Samsung Quick Share that could allow attackers within wireless range to crash or disrupt ...

The frontier model is a commodity. The companies winning are the ones that own distribution, and venture capital is paying up for it.